CME: Diabetic Retinopathy: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

Diabetic Retinopathy: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

Diabetic Retinopathy: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

What steps can we take to prevent vision loss in the nearly 8 million patients with diabetic retinopathy?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Even though diabetic retinopathy is the leading cause of blindness among U.S. adults, a substantial number of patients with diabetes are not receiving routine eye exams and are at risk of vision loss. Making matters worse is the fact that many patients with diabetes remain unaware that this disease can affect their vision. That’s why this discussion with a panel of expert faculty will examine what it means to be proactive in promoting vision screening and minimizing the risk for vision loss with appropriate early treatment in these patients.

    Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Janine Austin Clayton, MD

    NIH Associate Director for Research on Women’s Health
    Director, NIH Office of Research on Women’s Health
    Bethesda, MD

    Dr. Austin Clayton has nothing to disclose.

    A. Paul Chous, MA, OD, FAAO, CDE
    Medical Director
    Chous Eye Care Associates
    Maple Valley, WA

    Consulting Fees: Genentech, Regeneron, ZeaVision, LLC, Zeiss
    Royalties: ZeaVision, LLC

    Anne Peters, MD
    Director, USC Clinical Diabetes Program
    Professor of Clinical Medicine
    Los Angeles, CA

    Consulting Fees: Abbott Diabetes Care, Bigfoot, Eli Lilly and Company, Livongo, MannKind, Novo Nordisk, Sanofi, Whole Biome
    Research Support: Dexcom, vTvTherapeutics
    Commercial Interest Speakers Bureau: Novo Nordisk
    Stock Options: Mellitus Health, Omada Health, Stability Health, Whole Biome, Livongo

    Charles Wykoff, MD, PhD
    Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
    Associate Clinical Member, Research Institute
    Houston Methodist
    Weill Cornell Medical College
    Houston, TX

    Consulting Fees: Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Fosun, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, Polyphotonix, RecensMedical, Regeneron, Regenxbio, Roche, Santen, Takeda
    Commercial Interest Speakers Bureau: Regeneron
    Research Grant Support: Adverum, Aerpio, Allergan, Apellis, Chengdu, Kanghong, Clearside Biomedical, Genentech, Iveric Bio (formerly Ophthotech), Kodiak, Neurotech, Novartis, Opthea, RecensMedical, Regeneron, Regenxbio, Roche, Samsung, Santen

    Reviewers/Content Planners/Authors: (should be listed in alphabetical order)

    • All PIM planners and managers have no conflicts to report.
    • Rob Braun has nothing to disclose.
    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Robert S. Schneider, MSW has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss how timely referral and early diagnosis can prevent and minimize the risk for vision-threatening complications
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists, retina specialists, optometrists, eye health nurses, clinical endocrinologists, diabetologists, primary care physicians, nurse practitioners, physician assistants, and nurses.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This Enduring Material activity, Diabetic Retinopathy: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 09/15/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Approved for 0.25 AAFP Prescribed credits.

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Review Group Vision Care Education.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

    This course is COPE approved for 0.25 hours of CE credit. Course ID is 64690-PS. Check with your local state licensing board to see if this counts toward your CE requirement for relicensure.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free